On 27 February 2026, a working meeting was held to discuss the current status and future development prospects of the biopharmaceutical cluster in the Kirov Region. The meeting took place at Nanolek’s production site, the region’s leading biopharmaceutical enterprise.
The discussion brought together representatives of the regional government, the Legislative Assembly of the Kirov Region, and the company’s management team.
Roman Beresnev, Chairman of the Legislative Assembly of the Kirov Region, outlined key support measures for the industry:
“The industry has strong prospects. It is essential to strengthen the foundation for such projects and support them through tax incentives. Just last week, the Legislative Assembly unanimously approved a reduction in the corporate profit tax rate for participants in regional investment projects. We are ready to continue legislative efforts, if necessary, to attract investors and foster innovation — especially in the districts. We know this is achievable from the example of Nanolek. The company has built an advanced manufacturing facility, become a reliable employer, and a responsible social partner for local authorities.”
Denis Pestrikov, Acting Deputy Chairman of the Government of the Kirov Region and Minister of Industry of the Kirov Region, presented a report on the current state of the sector and its development outlook:
“Biopharmaceuticals can become one of the key drivers of industrial growth in the Kirov Region. This sector creates new competencies and new centers of economic development, opening up high-tech opportunities for the region.”
Natalia Kryazheva, Minister of Economic Development of the Kirov Region, presented measures aimed at stimulating investment activity, including industrial support instruments and strategic project facilitation.
“We are building a comprehensive investor support system — from tax incentives to personalized support for investment projects under a ‘one-stop shop’ principle. We are creating conditions in which businesses see long-term prospects and are ready to invest in our shared future,” she noted.
Alexey Pavlov, Director of the Biomedical Complex, spoke about Nanolek’s current investment activities, ongoing projects, and plans to expand production capacity. The focus was on scaling up manufacturing capabilities, developing full-cycle production of vaccines and biotechnological products, and further strengthening the company’s technological base.
Nanolek is one of the largest biopharmaceutical manufacturing complexes in the region and a systemically important enterprise for the Kirov Region. For five consecutive years, the company has ranked among the region’s largest taxpayers. Its production site in Levintsy implements full-cycle projects — from technology transfer and localization to commercial manufacturing in accordance with international GMP standards.
In recent years, the company has invested significant resources in developing modern infrastructure, launching new production units, and strengthening its human capital. These projects are aimed at enhancing Russia’s technological independence in vaccines and biopharmaceuticals, as well as building sustainable domestic manufacturing supply chains.
Nanolek is currently bringing to market the first* Russian vaccine for the prevention of human papillomavirus (HPV). The virus is responsible for a number of oncological diseases and is considered a priority for inclusion in the expanded National Immunization Schedule. In 2026, the company plans to produce approximately 600,000 doses of the vaccine. Following capacity expansion, annual output is expected to reach up to 3 million doses, ensuring supply for the national healthcare system.
The meeting confirmed the strong cooperation between business and regional authorities in advancing high-tech industries. Participants emphasized that further expansion of the biopharmaceutical cluster in the Kirov Region will strengthen the region’s industrial capacity and enhance its role in the federal technological development agenda.
*https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=28c34cae-5bcb-4795-9417-1264be63b56f